SG158148A1 - Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides - Google Patents

Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides

Info

Publication number
SG158148A1
SG158148A1 SG200908439-3A SG2009084393A SG158148A1 SG 158148 A1 SG158148 A1 SG 158148A1 SG 2009084393 A SG2009084393 A SG 2009084393A SG 158148 A1 SG158148 A1 SG 158148A1
Authority
SG
Singapore
Prior art keywords
natural amino
polypeptides
amino acids
amino acid
methods
Prior art date
Application number
SG200908439-3A
Other languages
English (en)
Inventor
Zhenwei Miao
Junjie Liu
Thea Norman
Russell Driver
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of SG158148A1 publication Critical patent/SG158148A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/08—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C07C225/10—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms not being part of rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/28—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/54—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/60—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/89—Benzo [c] furans; Hydrogenated benzo [c] furans with two oxygen atoms directly attached in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
SG200908439-3A 2004-12-22 2005-12-21 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides SG158148A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US63919504P 2004-12-22 2004-12-22
US63841804P 2004-12-22 2004-12-22
US63852704P 2004-12-22 2004-12-22
US69630205P 2005-07-01 2005-07-01
US69621005P 2005-07-01 2005-07-01
US69606805P 2005-07-01 2005-07-01

Publications (1)

Publication Number Publication Date
SG158148A1 true SG158148A1 (en) 2010-01-29

Family

ID=36602327

Family Applications (3)

Application Number Title Priority Date Filing Date
SG200908439-3A SG158148A1 (en) 2004-12-22 2005-12-21 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
SG200908440-1A SG158149A1 (en) 2004-12-22 2005-12-21 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
SG200908678-6A SG158186A1 (en) 2004-12-22 2005-12-21 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG200908440-1A SG158149A1 (en) 2004-12-22 2005-12-21 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
SG200908678-6A SG158186A1 (en) 2004-12-22 2005-12-21 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides

Country Status (16)

Country Link
US (20) US7385028B2 (ko)
EP (2) EP2399893B1 (ko)
JP (1) JP5425398B2 (ko)
KR (1) KR101423769B1 (ko)
CN (1) CN104803865A (ko)
AU (2) AU2005319125A1 (ko)
BR (1) BRPI0516385B1 (ko)
CA (3) CA3005835C (ko)
DK (2) DK1828224T3 (ko)
GB (1) GB2438982A (ko)
HK (1) HK1111702A1 (ko)
IL (3) IL183346A (ko)
MX (1) MX2007007590A (ko)
NZ (1) NZ555308A (ko)
SG (3) SG158148A1 (ko)
WO (1) WO2006069246A2 (ko)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US20220144872A1 (en) * 2003-02-19 2022-05-12 Panion & Bf Biotech Inc. Pharmaceutical-Grade Ferric Organic Compounds, Uses Thereof and Methods of Making Same
US20050287639A1 (en) 2004-05-17 2005-12-29 California Institute Of Technology Methods of incorporating amino acid analogs into proteins
EP1805217A2 (en) * 2004-10-18 2007-07-11 Novo Nordisk A/S Method for the preparation of oxime, thiazolidine, dithiane, dithiolane or hydrazone linked analogues of growth hormone
CA3005835C (en) 2004-12-22 2023-01-31 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US7906024B2 (en) * 2005-01-25 2011-03-15 Wyeth Research Ireland Limited Shear protectants in harvest microfiltration
US20070122408A1 (en) * 2005-10-20 2007-05-31 The Scripps Research Institute Fc Labeling for Immunostaining and Immunotargeting
NZ567234A (en) 2005-11-08 2011-09-30 Ambrx Inc Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
CA2631491C (en) * 2005-12-14 2015-02-24 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
PL1986612T3 (pl) * 2006-02-07 2013-02-28 Shire Human Genetic Therapies Stabilizowana kompozycja glukocerebrozydazy
PL1999259T3 (pl) 2006-03-03 2015-01-30 California Inst Of Techn Specyficzne miejscowo wprowadzanie aminokwasów do cząsteczek
US7964181B2 (en) * 2006-03-30 2011-06-21 Palatin Technologies, Inc. Amino acid surrogates for peptidic constructs
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
US8114844B2 (en) * 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
AU2007292903B2 (en) 2006-09-08 2012-03-29 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
WO2008049034A1 (en) * 2006-10-17 2008-04-24 Zymera, Inc. System for assays of aminotranferase
WO2008081024A1 (en) * 2007-01-03 2008-07-10 Novo Nordisk Health Care Ag Subcutaneous administration of coagulation factor viia-related popypeptdes
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
NZ580686A (en) 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
WO2009036460A2 (en) * 2007-09-14 2009-03-19 Ambrx, Inc. Modified human apolipoprotein a-i polypeptides and their uses
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
US8647840B2 (en) 2007-12-11 2014-02-11 The Scripps Research Institute In vivo unnatural amino acid expression in the methylotrophic yeast Pichia pastoris
US8101706B2 (en) * 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
EP3042922B1 (en) 2008-01-11 2017-07-19 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
NZ602170A (en) * 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
DE102008002209A1 (de) * 2008-06-04 2009-12-10 Evonik Degussa Gmbh Verfahren zur Aufreinigung von Erythropoietin
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
US20090197339A1 (en) * 2008-12-10 2009-08-06 The Scripps Research Institute In vivo unnatural amino acid expression in the methylotrophic yeast pichia pastoris
JP5959201B2 (ja) * 2008-12-10 2016-08-02 ザ スクリプス リサーチ インスティテュート 化学的に反応性の非天然アミノ酸を使用するキャリア−ペプチド接合体の製造
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
WO2010105227A1 (en) * 2009-03-13 2010-09-16 Aerovance, Inc. Methods of renaturation of recombinant proteins
DE102009015347A1 (de) * 2009-03-27 2010-09-30 Man Nutzfahrzeuge Aktiengesellschaft Dieselkraftstoff auf Ethanol-Basis
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
CN105126086B (zh) 2009-07-28 2019-05-14 夏尔人类遗传性治疗公司 用于治疗戈谢病的组合物和方法
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
US8921571B2 (en) 2009-10-06 2014-12-30 The Ohio State University Pyrrolysine analogs
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
US20110160143A1 (en) * 2009-12-28 2011-06-30 Perricone Nicholas V Topical Acyl Glutathione Psoriasis Compositions
ES2802623T3 (es) 2010-01-27 2021-01-20 Massachusetts Inst Technology Agentes polipeptídicos técnicamente diseñados para la neutralización dirigida de amplio espectro de la gripe
JP5794558B2 (ja) * 2010-03-24 2015-10-14 国立研究開発法人産業技術総合研究所 改変された致死遺伝子及び該遺伝子を含むベクター
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
PL2605789T3 (pl) 2010-08-17 2019-11-29 Ambrx Inc Zmodyfikowane polipeptydy relaksyny i ich zastosowania
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CA2822591C (en) 2010-12-22 2020-12-29 Baxter International Inc. Materials and methods for conjugating a water soluble fatty acid derivative to a protein
AU2012205301B2 (en) 2011-01-14 2017-01-05 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
JP2013199466A (ja) * 2012-02-24 2013-10-03 Fujifilm Corp リコピン含有組成物
CN104244989A (zh) * 2012-02-29 2014-12-24 Ambrx公司 含有新颖前药的分子组合物和其用途
AU2013225816B2 (en) 2012-03-02 2017-10-26 Takeda Pharmaceutical Company Limited Compositions and methods for treating Type III Gaucher Disease
EP3492101A3 (en) 2012-05-10 2019-10-23 Massachusetts Institute Of Technology Agents for influenza neutralization
CN108727466B (zh) * 2012-06-07 2023-04-28 Ambrx公司 前列腺特异性膜抗原抗体药物结合物
ES2718478T3 (es) 2012-06-08 2019-07-02 Sutro Biopharma Inc Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
WO2013192360A1 (en) 2012-06-19 2013-12-27 Ambrx, Inc. Anti-cd70 antibody drug conjugates
GB201211353D0 (en) 2012-06-26 2012-08-08 Cm Online Ltd Interactive video
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
AU2013308494B2 (en) 2012-08-31 2018-03-01 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
CN103933575B (zh) 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
US10233249B2 (en) 2013-03-19 2019-03-19 Beijing Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
CA2965502A1 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
WO2016069726A1 (en) * 2014-10-28 2016-05-06 President And Fellows Of Harvard College Methods of making polypeptides with non-standard amino acids using genomically recoded organisms
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
EP3903826B1 (en) 2014-12-04 2024-05-08 Celgene Corporation Biomolecule conjugates
SG11201708762QA (en) * 2015-03-31 2017-11-29 Eiken Chemical Preservative solution for heme protein, and method for stabilizing heme protein
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR20180104106A (ko) 2016-01-27 2018-09-19 서트로 바이오파마, 인크. anti-CD74 항체 접합체, anti-CD74 항체 접합체를 포함하는 조성물 및 anti-CD74 항체 접합체의 이용 방법
WO2017161183A1 (en) 2016-03-16 2017-09-21 The Regents Of The University Of California Covalent peptide binders
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
US20210308277A1 (en) 2016-11-14 2021-10-07 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
EP4066850A3 (en) 2017-02-22 2022-11-23 Bioincept LLC Peptides and methods of treating dystrophy-related disorders using the same
CA3061340A1 (en) 2017-04-25 2018-11-01 Temple Otorongo Llc Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
WO2019006690A1 (zh) * 2017-07-05 2019-01-10 拜西欧斯（北京）生物技术有限公司 多肽的药学可接受的盐及其应用
EP3655010A4 (en) 2017-07-17 2021-06-09 Bioincept LLC PEPTIDES AND METHODS FOR TRANSPLANTATION AND RESTORATIVE ORGAN FUNCTION
AU2019231893A1 (en) * 2018-03-08 2020-10-29 The Regents Of The University Of California Bioreactive compositions and methods of use thereof
CN108538399A (zh) * 2018-03-22 2018-09-14 复旦大学 一种磁共振肝癌疗效评估方法和系统
IL308797A (en) 2018-03-28 2024-01-01 Ascendis Pharma Oncology Div A/S IL-2 conjugates
AU2019246390A1 (en) 2018-03-28 2020-08-06 Ascendis Pharma A/S Conjugates
CN110760306B (zh) * 2018-07-27 2021-11-23 Tcl科技集团股份有限公司 一种量子点的提纯方法
CA3110647A1 (en) 2018-08-28 2020-03-05 Ambrx, Inc. Anti-cd3 antibody folate bioconjugates and their uses
JP2021536263A (ja) * 2018-09-07 2021-12-27 メディミューン，エルエルシー 細胞選択の方法
EP3849614B1 (en) 2018-09-11 2023-12-20 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
CN113366015A (zh) 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途
SG11202108254YA (en) 2019-02-12 2021-08-30 Ambrx Inc Compositions containing, methods and uses of antibody-tlr agonist conjugates
KR20210132104A (ko) 2019-02-19 2021-11-03 울티마 제노믹스, 인크. 광학 검출 및 시퀀싱을 위한 링커 및 방법
KR20220029725A (ko) 2019-06-29 2022-03-08 항저우 디에이씨 바이오테크 씨오, 엘티디 세포-결합 분자-튜불리신 유도체 접합체 및 이의 제조 방법
WO2021102624A1 (en) * 2019-11-25 2021-06-03 Hangzhou Branch Of Technical Institute Of Physics And Chemistry, Chinese Academy Of Sciences Covalent protein drugs developed via proximity-enabled reactive therapeutics (perx)
US11807851B1 (en) 2020-02-18 2023-11-07 Ultima Genomics, Inc. Modified polynucleotides and uses thereof
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
US20230193398A1 (en) * 2020-04-22 2023-06-22 Nicca Chemical Co., Ltd. Nucleic acid detection method and oligonucleotide probe
CN112028987B (zh) * 2020-06-01 2021-07-30 广东圣赛生物科技有限公司 一种结合免疫抑制分子pd-l1的蛋白药物
IL298642A (en) 2020-06-03 2023-01-01 Ascendis Pharma Oncology Div A/S il-2 sequences and uses thereof
WO2022040213A1 (en) * 2020-08-18 2022-02-24 Ultima Genomics, Inc. Reagents for labeling biomolecules
EP4199968A1 (en) 2020-08-20 2023-06-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
CN114573714B (zh) * 2021-03-15 2023-03-31 北京大学 用于靶分子修饰的缀合物及其制备方法
IL307282A (en) 2021-04-03 2023-11-01 Ambrx Inc Antidote conjugates against HER2 and their applications
EP4330214A2 (en) * 2021-04-28 2024-03-06 The Regents of the University of California Bioreactive proteins containing unnatural amino acids
EP4366779A1 (en) 2021-07-09 2024-05-15 Bright Peak Therapeutics AG Modified tnf-antibodies and uses thereof
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
AU2022306788A1 (en) 2021-07-09 2024-01-04 Bright Peak Therapeutics Ag Conjugates of checkpoint inhibitors with il-2, and uses thereof
KR20240041379A (ko) 2021-07-09 2024-03-29 브라이트 피크 테라퓨틱스 아게 Il-2에 접합된 체크포인트 억제제 및 이의 용도
WO2023281481A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Antibody conjugates and manufacture thereof
WO2023161854A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
WO2023161857A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
WO2024077277A1 (en) 2022-10-07 2024-04-11 Ambrx, Inc. Drug linkers and antibody conjugates thereof
KR102526689B1 (ko) * 2022-11-24 2023-04-28 주식회사 리얼이펙트 양친매성 항균펩타이드인 알루미늄 팔미토일다이펩타이드-4를 포함하는 액정수화 화장료 조성물
KR102524528B1 (ko) * 2022-11-24 2023-04-21 주식회사 리얼이펙트 양친매성 항균펩타이드인 알루미늄 팔미토일다이펩타이드의 제조방법

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US644281A (en) * 1899-12-01 1900-02-27 Samuel Crump Process of drying and varnishing prints.
US3849576A (en) * 1964-01-29 1974-11-19 Oreal Process and cosmetic compositions for the treatment of skin and scalp
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB1366554A (en) * 1972-03-06 1974-09-11 Science Union & Cie Phenylalanine derivatives and a process for their preparation
US4272432A (en) * 1974-11-13 1981-06-09 American Home Products Corporation Claudogenic-interceptive nonapeptide
ZA783356B (en) * 1977-07-21 1979-06-27 Merrell Toraude & Co A-halomethyl amino acid derivatives
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
DE3043159C2 (de) * 1980-11-15 1982-12-09 Degussa Ag, 6000 Frankfurt Cyclische Acetale des Glutaminsäure-γ-semialdehyds, Verfahren zu deren Herstellung und ihre Verwendung
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4820352A (en) 1983-01-10 1989-04-11 Bausch & Lomb Incorporated Cleaning and conditioning solutions for contact lenses and methods of use
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
CA1341116C (en) 1983-02-22 2000-10-17 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis or foreign protein
US5089398A (en) 1983-02-22 1992-02-18 Chiron Corporation Enhanced yeast transcription employing hybrid GAPDH promoter region constructs
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法
EP0127839B1 (en) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
ATE59966T1 (de) 1983-09-26 1991-02-15 Ehrenfeld Udo Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
ATE102250T1 (de) 1984-05-11 1994-03-15 Chiron Corp Erhoehte hefetranskription unter verwendung einer hybridkonstruktion der promotorregion.
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
DE3680924D1 (de) 1985-01-14 1991-09-26 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
JPS61243018A (ja) 1985-04-18 1986-10-29 Taisho Pharmaceut Co Ltd 真菌症治療剤
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5186933A (en) 1986-12-30 1993-02-16 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system
WO1988007082A1 (en) 1987-03-16 1988-09-22 American Biogenetic Sciences, Inc. Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
EP0284044B1 (en) 1987-03-23 1994-03-23 Zymogenetics, Inc. High level expression in yeast
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
WO1989001037A1 (en) 1987-07-24 1989-02-09 Cetus Corporation Production of ricin toxins in a baculovirus-insect cell expression system
AU2251488A (en) 1987-07-24 1989-03-01 Cetus Corporation Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
JPH02500880A (ja) 1987-11-18 1990-03-29 カイロン　コーポレイション Ｎａｎｂｖの診断用薬およびワクチン
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
EP0355147B1 (en) 1988-01-13 1995-04-19 Institut Pasteur Dna probe specific for pathogenic listeria
CA1324969C (en) 1988-05-06 1993-12-07 Jeffrey R. Shuster High level expression of proteins in yeast
US5674706A (en) 1988-05-06 1997-10-07 Chiron Corporation High level expression of proteins in yeast
FR2631974B1 (fr) 1988-05-31 1992-12-11 Agronomique Inst Nat Rech Baculovirus modifie, son procede de preparation et son application en tant que vecteur d'expression de genes
WO1990001556A1 (en) 1988-08-05 1990-02-22 Mount Sinai School Of Medicine Of The City University Of New York In vivo infection of live insects with a recombinant baculovirus
GB8819453D0 (en) 1988-08-16 1988-09-21 Roy P Production of bluetongue virus non-structural proteins using baculovirus expression vector
NZ230425A (en) 1988-09-02 1992-07-28 Molecular Eng Ass Production of paramyxovirus fusion (f) protein using recombinant baculovirus expression vector
JPH04504651A (ja) 1988-11-18 1992-08-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 自然に存在しないアミノ酸をタンパク質に部位特異的に導入する方法
AU5187190A (en) 1989-02-23 1990-09-26 University Of Ottawa Improved baculovirus expression system capable of producing foreign gene proteins at high levels
WO1990010277A1 (en) 1989-02-24 1990-09-07 Cell Analysis Systems, Inc. Method and apparatus for determining a proliferation index of a cell sample
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ES2247656T3 (es) 1989-04-19 2006-03-01 Enzon, Inc. Un proceso para formar un polipeptido modificado que comprende un polipeptido y un oxido de polialquileno.
JPH04501065A (ja) 1989-05-17 1992-02-27 ユニバーシティ オブ ジョージア リサーチ ファウンデーション インコーポレイテッド 改良されたバキュロウイルス発現ベクター
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5312808A (en) 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US5364840A (en) * 1989-12-05 1994-11-15 Vical, Inc. Synthetic calcitonin peptides
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
CA2018801C (en) * 1990-06-12 2000-08-22 Pierre Louis Beaulieu Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus
FR2664905B1 (fr) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
WO1992001800A1 (en) 1990-07-20 1992-02-06 Chiron Corporation Method for integrative transformation of yeast using dispersed repetitive elements
FR2665923B1 (fr) 1990-08-14 1993-01-22 Arbona Jean Unite de soins modulaire.
EP0548267A4 (en) 1990-09-04 1994-11-23 Salk Inst Biotech Ind Production of insulin-like growth factor-1 in methylotrophic yeast cells
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5231178A (en) 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
AU1651992A (en) 1991-03-19 1992-10-21 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Expression of influenza nucleoprotein antigens in baculovirus
US6126944A (en) 1991-04-26 2000-10-03 The United States Of America As Represented By The Department Of Health And Human Services Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5290686A (en) 1991-07-31 1994-03-01 The United States Of America As Represented By The Department Of Health And Human Services Expression of influenza a M2 protein in baculovirus
IT1260468B (it) 1992-01-29 1996-04-09 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
EP0636156B1 (en) 1992-04-14 1997-07-30 Cornell Research Foundation, Inc. Dendritic based macromolecules and method of production
US5516657A (en) 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
WO1994004193A1 (en) 1992-08-21 1994-03-03 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
CA2110543A1 (en) 1992-12-09 1994-06-10 David E. Wright Peg hydrazone and peg oxime linkage forming reagents and protein derivatives thereof
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5464820A (en) * 1993-06-22 1995-11-07 The University Hospital Specific inhibitors of tissue kallikrein
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
DE4335555A1 (de) * 1993-10-19 1995-04-20 Basf Ag Oximether und diese enthaltende Copolymerisate
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605792A (en) 1993-11-04 1997-02-25 The Ohio State University Research Foundation Infectious bursal disease virus VP2 fusion protein expressed by baculovirus, use as diagnostic
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
FR2715664B1 (fr) 1994-01-31 1996-04-12 Proteine Performance Sa Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux.
JP3090586B2 (ja) 1994-03-15 2000-09-25 片倉工業株式会社 システインプロテアーゼ遺伝子欠損バキュロウイルスおよびその製造法並びにこれを利用する有用タンパク質の製造法
US6403375B1 (en) 1994-08-24 2002-06-11 Boyce Thompson Institute For Plant Research, Inc. Establishment of Trichoplusia ni cell lines in serum-free medium for recombinant protein and baculovirus production
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996041813A2 (en) 1994-11-09 1996-12-27 Offord Robin E Functionalized polymers for site-specific attachment
IL116085A (en) 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
AU720337B2 (en) 1995-02-17 2000-05-25 Stichting Dienst Landbouwkundig Onderzoek Production of biologically active recombinant bovine follicle stimulating hormone (REC bFSH) in the baculovirus expression system
FR2732035B1 (fr) 1995-03-23 1997-05-30 Agronomique Inst Nat Rech Procede de regulation de l'expression d'un gene dans un baculovirus, par un site de fixation d'un recepteur de l'acide retinoique, et vecteur pour la mise en oeuvre du dit procede
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
NZ308772A (en) 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
JPH09157578A (ja) * 1995-12-08 1997-06-17 Daikin Ind Ltd 含フッ素塗料用材料およびそれを用いた被覆方法
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
AU1690697A (en) 1996-01-17 1997-08-11 Schering Corporation Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin antagonists
US5861279A (en) 1996-01-17 1999-01-19 Schering Corporation Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists
US5876916A (en) * 1996-03-18 1999-03-02 Case Western Reserve University Pyruvate compounds and methods for use thereof
US6077939A (en) 1996-08-02 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Methods and kits for making polypeptides having a single covalently bound N-terminal water-soluble polymer
ATE253120T1 (de) 1996-12-13 2003-11-15 Chiron Corp Verfahren zur expression von heterologen proteinen in hefe
GB9703406D0 (en) 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
WO1998055630A2 (en) * 1997-06-06 1998-12-10 The Governors Of The University Of Alberta Alpha-1,3-fucosyltransferase of helicobacter pylori
US5965393A (en) 1997-07-01 1999-10-12 National Institute Of Immunology Method for enhancing foreign gene expression in baculovirus expression vector system
WO1999003887A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
GB9715660D0 (en) 1997-07-25 1997-10-01 Zeneca Ltd Proteins
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
EP1003889A1 (en) 1997-08-05 2000-05-31 Chiron Corporation NOVEL $i(PICHIA PASTORIS) GENE SEQUENCES AND METHODS FOR THEIR USE
DE19735593C2 (de) 1997-08-15 1999-08-26 Hepavec Ag Fuer Gentherapie Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie
US6090584A (en) 1997-08-21 2000-07-18 University Technologies International Inc. Baculovirus artificial chromosomes and methods of use
US6455550B1 (en) 1997-08-22 2002-09-24 Hoffmann-La Roche Inc. N-alkanoylphenylalanine derivatives
DK1015576T3 (da) 1997-09-16 2005-08-29 Egea Biosciences Llc Fremgangsmåde til fuldstændig kemisk syntese og aggregering af gener og genomer
US6449281B1 (en) 1997-09-30 2002-09-10 Intel Corporation Interface control of communication between a control processor and a digital signal processor
JPH11140076A (ja) * 1997-11-04 1999-05-25 Dai Ichi Pure Chem Co Ltd Ｎ−アシル−α−アミノアジピン酸−γ−セミアルデヒドエチレンアセタール
EP0924298A1 (en) 1997-12-18 1999-06-23 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Protein expression in baculovirus vector expression systems
JP2002505110A (ja) 1998-03-04 2002-02-19 オニックス ファーマシューティカルズ，インコーポレイティド 遺伝物質の高生産性発現のためのバキュロウイルス発現系及び方法
WO1999045026A1 (en) 1998-03-05 1999-09-10 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
SK13012000A3 (sk) 1998-03-11 2001-06-11 G. D. Searle & Co. Halogenované deriváty amidinoaminokyselín použiteľné ako inhibítory no-syntázy
KR100264953B1 (ko) 1998-04-03 2001-03-02 박현우 재조합 베큘로바이러스, 이의 제조방법 및 이를 포함하는 미생물 살충제
US6168932B1 (en) 1998-07-13 2001-01-02 Parker Hughes Institute Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system
US6245528B1 (en) 1998-07-28 2001-06-12 Academia Sinica Latent baculovirus expression system
US6368825B1 (en) 1998-08-10 2002-04-09 Academia Sinica Baculovirus containing minimal CMV promoter
AU6059699A (en) * 1998-09-23 2000-04-10 Regents Of The University Of California, The Synthetic peptides, conjugation reagents and methods
WO2000020032A1 (en) 1998-10-06 2000-04-13 Trustees Of Dartmouth College RECOMBINANT CAT ALLERGEN, Fel dI, EXPRESSED IN BACULOVIRUS FOR DIAGNOSIS AND TREATMENT OF CAT ALLERGY
US6342216B1 (en) 1999-03-17 2002-01-29 The Board Of Regents, The University Of Texas System Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
US6994986B2 (en) 1999-03-17 2006-02-07 The Board Of Trustees Of The Leland Stanford University In vitro synthesis of polypeptides by optimizing amino acid metabolism
WO2000055353A1 (en) 1999-03-17 2000-09-21 The Board Of Trustees Of The Leland Stanford Junior University In vitro macromolecule biosynthesis methods using exogenous amino acids and a novel atp regeneration system
US6337191B1 (en) 1999-03-22 2002-01-08 The Board Of Trustees Of The Leland Stanford Junior University Vitro protein synthesis using glycolytic intermediates as an energy source
US6312725B1 (en) * 1999-04-16 2001-11-06 Cohesion Technologies, Inc. Rapid gelling biocompatible polymer composition
US6261805B1 (en) 1999-07-15 2001-07-17 Boyce Thompson Institute For Plant Research, Inc. Sialyiation of N-linked glycoproteins in the baculovirus expression vector system
WO2001027301A2 (en) 1999-10-15 2001-04-19 The Rockefeller University System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
GB9929613D0 (en) * 1999-12-15 2000-02-09 Koninkl Philips Electronics Nv Manufacture of semiconductor material and devices using that material
SE0000055D0 (sv) * 2000-01-10 2000-01-10 Centaur Pharmaceuticals Inc Novel process
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
GB0012997D0 (en) 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
CN1245974C (zh) * 2000-06-28 2006-03-22 特瓦制药工业有限公司 卡维地洛
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
JP2002030098A (ja) 2000-07-17 2002-01-29 Institute Of Immunology Co Ltd バキュロウィルスの発芽ウイルスからウイルスエンベロープを回収する方法
US20030191291A1 (en) 2000-09-08 2003-10-09 Kochendoerfer Gerd G. Synthetic erythropoiesis stimulating proteins
CA2444098C (en) 2001-04-19 2016-06-21 The Scripps Research Institute Methods and composition for the production of orthogonal trna-aminoacyltrna synthetase pairs
US6608196B2 (en) * 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
ATE408593T1 (de) * 2001-05-03 2008-10-15 Galileo Lab Inc Pyruvatderivate
GB0113657D0 (en) 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
US20030154058A1 (en) * 2001-06-11 2003-08-14 Keener Bryan F. Methods and systems for validating translated geometry
US20040138412A1 (en) 2001-09-07 2004-07-15 Paolo Botti Extended native chemical ligation
WO2003022261A1 (en) * 2001-09-13 2003-03-20 Miller Kenneth E Method of alleviating pain
AU2002352524B2 (en) 2001-11-07 2007-10-04 Nektar Therapeutics Branched polymers and their conjugates
US7884182B2 (en) 2001-11-14 2011-02-08 Amylin Pharmaceuticals, Inc. Chemical peptide ligation with three or more components
KR20070072924A (ko) * 2001-11-20 2007-07-06 파마시아 코포레이션 화학적으로 개질된 인간 성장 호르몬 콘쥬게이트
PT1578949E (pt) 2002-10-16 2009-07-14 Scripps Research Inst Incorporação específica do local de cetoaminoácidos em proteínas
MXPA05006836A (es) 2002-12-22 2005-08-16 Scripps Research Inst Colecciones ordenadas de proteinas.
ES2308032T5 (es) * 2002-12-31 2017-04-24 Nektar Therapeutics Derivados poliméricos de ácido maleámico y sus bioconjugados
WO2004072243A2 (en) * 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
CN103215228A (zh) 2003-04-17 2013-07-24 斯克利普斯研究院 扩展真核生物遗传密码
EP1663302B1 (en) * 2003-09-03 2012-06-13 Alpharma, LLC Method for vaccination of poultry by bacteriophage lysate
CA2594557C (en) * 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
CA3005835C (en) 2004-12-22 2023-01-31 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
JP4478883B2 (ja) * 2005-03-25 2010-06-09 ヤマハ株式会社 音楽再生装置およびプログラム
DE102005036719A1 (de) * 2005-07-28 2007-02-01 Carl Zeiss Industrielle Messtechnik Gmbh Verfahren zum Korrigieren von Interpolationsfehlern einer Maschine, insbesondere eines Koordinatenmessgerätes
NZ567234A (en) 2005-11-08 2011-09-30 Ambrx Inc Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
CA2631491C (en) 2005-12-14 2015-02-24 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
JP2009522275A (ja) 2005-12-30 2009-06-11 アンブルックス，インコーポレイテッド 非天然アミノ酸およびポリペプチドを含んでいる組成物、それらに関する方法、ならびに、それらの使用
US7760037B2 (en) * 2007-03-28 2010-07-20 Intel Corporation Process, voltage, and temperature compensated clock generator
US20090113333A1 (en) 2007-10-26 2009-04-30 Palm, Inc. Extendable Toolbar for Navigation and Execution of Operational Functions

Also Published As

Publication number Publication date
WO2006069246A9 (en) 2006-08-31
CA2927595A1 (en) 2006-06-29
GB0713066D0 (en) 2007-08-15
AU2010226982A1 (en) 2010-10-28
EP1828224A4 (en) 2009-02-25
IL227753A0 (en) 2013-09-30
US8809511B2 (en) 2014-08-19
US20150094457A1 (en) 2015-04-02
CA2927595C (en) 2023-01-31
HK1111702A1 (zh) 2008-08-15
KR101423769B1 (ko) 2014-07-30
US20130030160A1 (en) 2013-01-31
US20080177038A1 (en) 2008-07-24
US20060194256A1 (en) 2006-08-31
CA2590590A1 (en) 2006-06-29
JP2008545371A (ja) 2008-12-18
DK2399893T3 (en) 2018-10-08
EP2399893B1 (en) 2018-08-15
SG158149A1 (en) 2010-01-29
US8263740B2 (en) 2012-09-11
GB2438982A (en) 2007-12-12
US20080268519A1 (en) 2008-10-30
US8008456B2 (en) 2011-08-30
IL220740A (en) 2017-10-31
NZ555308A (en) 2010-10-29
EP1828224B1 (en) 2016-04-06
DK1828224T3 (en) 2016-07-18
US20080153979A1 (en) 2008-06-26
US8476411B2 (en) 2013-07-02
US8367612B2 (en) 2013-02-05
BRPI0516385B1 (pt) 2021-07-20
MX2007007590A (es) 2007-12-10
CN104803865A (zh) 2015-07-29
IL183346A0 (en) 2007-09-20
US20080177027A1 (en) 2008-07-24
CA2590590C (en) 2016-04-19
US20080182969A1 (en) 2008-07-31
IL227753A (en) 2017-10-31
US20080182968A1 (en) 2008-07-31
US8791231B2 (en) 2014-07-29
US20110288279A1 (en) 2011-11-24
US20060217532A1 (en) 2006-09-28
SG158186A1 (en) 2010-01-29
US8846876B2 (en) 2014-09-30
US20110118451A1 (en) 2011-05-19
CA3005835A1 (en) 2006-06-29
US20090123968A1 (en) 2009-05-14
US7696312B2 (en) 2010-04-13
US20080213840A1 (en) 2008-09-04
US7928163B2 (en) 2011-04-19
US20110118501A1 (en) 2011-05-19
EP2399893A2 (en) 2011-12-28
US7332571B2 (en) 2008-02-19
US20100120686A1 (en) 2010-05-13
WO2006069246A3 (en) 2008-09-25
US9637441B2 (en) 2017-05-02
US7385028B2 (en) 2008-06-10
US20090111147A1 (en) 2009-04-30
IL220740A0 (en) 2012-08-30
EP2399893A3 (en) 2012-08-08
AU2010226982B2 (en) 2012-02-23
US8859802B2 (en) 2014-10-14
BRPI0516385A (pt) 2007-11-27
AU2005319125A1 (en) 2006-06-29
US20110124880A1 (en) 2011-05-26
WO2006069246A2 (en) 2006-06-29
US20060217289A1 (en) 2006-09-28
JP5425398B2 (ja) 2014-02-26
CA3005835C (en) 2023-01-31
US20080268518A1 (en) 2008-10-30
KR20070100749A (ko) 2007-10-11
US7638491B2 (en) 2009-12-29
US8048988B2 (en) 2011-11-01
IL183346A (en) 2014-06-30
EP1828224A2 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
SG158148A1 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2007079130A3 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2011028195A3 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
SG170116A1 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
MX2020001231A (es) Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
MX2021009644A (es) Composiciones que contienen, metodos y usos de conjugados de anticuerpo-agonista de tlr.
WO2007059312A3 (en) Methods and compositions comprising non-natural amino acids
MX2013013683A (es) Composiciones que contienen, metodos que involucran, y usos de derivados de dolastatina unidos a aminoacidos no naturales.
MX2009007001A (es) Aminoacidos y polipeptidos fenazina y quinoxalina sustituidos.
PT1969007E (pt) Composições e métodos para a produção de uma composição
WO2005119251A3 (en) Novel means and methods for the treatment of hearing loss and phantom hearing
EP3805248A3 (en) Process for concentration of antibodies and therapeutic products thereof
WO2006087550A3 (en) Amyloid-binding peptides, analogues and uses thereof
WO2007002261A3 (en) IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF
EP2284192A3 (en) Camelidae antibodies for sublingual administration
WO2005003296A3 (en) Albumin fusion proteins
WO2007056448A3 (en) Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
EP2631242A3 (en) A process for concentration of a polypeptide
ZA200708407B (en) IL-21 variants
WO2007149542A3 (en) Antimicrobial kinocidin compositions and methods of use
DE602006005898D1 (de) Verfahren zur herstellung von cyclohexanon und cyclohexanol
WO2004048517A3 (en) Method for reducing or preventing modification of a polypeptide in solution
DE60142239D1 (de) DEN PHOSPHORSÄURE-METABOLISMUS, DEN KALZIUM-METABOLISMUS, VERKALKUNG UND DEN VITAMIN D-METABOLISMUS KONTROLLIERENDE POLYPEPTIDE SOWIE FüR DIESE KODIERENDE DNA-MOLEKÜLE
WO2007093848A3 (en) Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof